During the past decade, The Alverton Practice conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 7 clinical trials were completed, i.e. on average, 116.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 4 clinical trials were completed. i.e. 400% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Alverton Practice" #1 sponsor was "Pfizer" with 2 trials, followed by "Artu Biologicals" with 1 trials sponsored, "BTG International Inc." with 1 trials sponsored, "Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company" with 1 trials sponsored and "Eli Lilly and Company" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Alverton Practice" #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator, "CoLucid Pharmaceuticals" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Encorium" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "The Alverton Practice" are "Atherosclerotic Cardiovascular Disease" (3 trials), "Familial Hypercholesterolemia" (2 trials), "Type2 Diabetes" (2 trials), "Allergic Rhinoconjunctivitis" (1 trials) and "Cardiovascular Disease" (1 trials). Many other conditions were trialed in "The Alverton Practice" in a lesser frequency.

Most popular intervention types in "The Alverton Practice" are "Drug" (8 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "ALN-PCSSC" (1 trials), "Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant" (1 trials), "CoVaccine HT™ adjuvant" (1 trials) and "Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Alverton Practice" are 9 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "The Alverton Practice". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in The Alverton Practice, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in The Alverton Practice, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".